This content is for subscribers only. Please click here to see our plans.
Similar Posts
Biotech News – August 11, 2026
This content is for subscribers only. Please click here to see our plans.
Biotech Stock Catalysts (Data)
This content is for subscribers only. Please click here to see our plans.
The Biotech Gamble
the biotech gamble Introduction In this article, we would like to introduce you to a very special type of share. These are biotech companies. These are companies that develop and market drugs, many of them only for extremely rare diseases. Many of them have a very low market capitalization (market value) of less than USD 100 million, some even less…
Biotech News – August 8, 2026
biotech & health insights 🧬 Biotech News Roundup: Major Movers, FDA Updates & Key Investor Takeaways Biotech stocks delivered a highly mixed session, with several companies posting major moves following earnings, regulatory updates, guidance changes and corporate developments. The biggest gainers included AVITA Medical, OmniAb and VivoSim Labs, while CVRx, QuidelOrtho, Ardelyx and BioVie faced significant selling pressure. Meanwhile, Scholar…
BioTech Market Insights
This content is for subscribers only. Please click here to see our plans.
Biotech Analyst Roundup – July 29, 2026
biotech analyst roundup Biotech Analyst Roundup: Psychedelics, Gene Therapy, Immunology & Regulatory Outlook Wall Street analysts delivered a wave of updated biotechnology research covering psychedelic medicine, rare diseases, immunology, ophthalmology, and oncology. While several companies continue to earn bullish ratings based on strong clinical pipelines and cash runways, others face valuation concerns, regulatory uncertainty, or commercialization challenges. Here’s a detailed…
